Kosan Biosciences Inc., of Hayward, Calif., was awarded U.S. Patent No. 6,410,301 covering the recombinant microorganism used to produce Epothilone D (KOS-862), Kosan's anticancer drug in Phase I trials.
Symyx Technologies Inc., of Santa Clara, Calif., was issued U.S. Patent No. 6,410,331 covering methods the company said are widely used for high-throughput screening of inorganic and organometallic materials for catalysis.
Vical Inc., of San Diego, was issued U.S. Patent No. 6,413,942 covering methods for the nonviral, gene-based delivery of physiologically active polypeptides or proteins, including growth hormone, insulin, interleukins, interferons, GM-CSF and erythropoietin.